Scarica l'app Stockscreener
27.39
3.54%
-0.613
Precedente Chiudi:
$28.00
Aprire:
$27.49
Volume 24 ore:
105.04K
Relative Volume:
0.41
Capitalizzazione di mercato:
$1.75B
Reddito:
-
Utile/perdita netta:
$-143.59M
Rapporto P/E:
-9.6993
EPS:
-2.8236
Flusso di cassa netto:
$-119.47M
1 W Prestazione:
-3.36%
1M Prestazione:
-2.88%
6M Prestazione:
+23.28%
1 anno Prestazione:
+76.31%
Intervallo 1D:
$26.11
$27.91
Intervallo di 1 settimana:
$26.11
$28.61
Portata 52W:
$11.51
$29.80
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
27.00 | 1.82B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.73 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.55 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.64 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.56 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
298.74 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-15 | Iniziato | H.C. Wainwright | Buy |
| 2025-10-09 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Iniziato | Guggenheim | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Iniziato | Wedbush | Outperform |
| 2023-08-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Iniziato | Bryan Garnier | Buy |
| 2022-09-13 | Ripresa | JMP Securities | Mkt Outperform |
| 2022-08-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-03-02 | Iniziato | BofA Securities | Neutral |
| 2021-03-02 | Iniziato | Morgan Stanley | Overweight |
| 2021-03-02 | Iniziato | Oppenheimer | Outperform |
| 2021-03-02 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Pharvaris Nv Borsa (PHVS) Ultime notizie
Movement Recap: How correlated is Pharvaris NV to the S P500July 2025 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Pharvaris N.V. (PHVS) Stock Analysis: Exploring a Promising 65.84% Potential Upside in Biotech - DirectorsTalk Interviews
Responsive Playbooks and the PHVS Inflection - Stock Traders Daily
PHVS: Oral HAE therapy shows strong phase III results, with NDA filing and key data expected this year - TradingView
PHVS Should I Buy - Intellectia AI
PHVS Stock Price and Chart — NASDAQ:PHVS - TradingView
Pharvaris N.V. (PHVS) Stock Analysis: A 65% Upside Potential In The Biotech Sector - DirectorsTalk Interviews
A Look At Pharvaris (PHVS) Valuation As Deucrictibant Advances With New Phase 3 And Phase 2 Data - Sahm
Bain Capital Life Sciences shows 4.3% Pharvaris (PHVS) ownership in Schedule 13G/A - Stock Titan
Understanding the Setup: (PHVS) and Scalable Risk - Stock Traders Daily
Aug Shorts: What is the Moat Score of Pharvaris N.V.2025 Buyback Activity & Smart Swing Trading Techniques - mfd.ru
Pharvaris N.V. (PHVS) Stock Analysis: Potential Upside Of 75% In The Biotech Sector - DirectorsTalk Interviews
Does Pharvaris N.V. stock have upside surprise potentialIPO Watch & Daily Profit Maximizing Trade Tips - mfd.ru
Will Pharvaris N.V. stock gain from lower inflationEarnings Summary Report & Accurate Trade Setup Notifications - mfd.ru
Will Pharvaris N.V. stock recover faster than peersQuarterly Portfolio Review & Comprehensive Market Scan Insights - mfd.ru
Aug Swings: How sensitive is Pharvaris NV to inflationQuarterly Investment Review & Daily Profit Maximizing Tips - baoquankhu1.vn
Oral drug for hereditary angioedema attacks shows Phase 3 data at AAAAI 2026 - Stock Titan
Aug Outlook: Is Pharvaris NV stock a value trapJuly 2025 Big Picture & High Return Trade Guides - baoquankhu1.vn
Aug Gainers: Can Pharvaris NV stock outperform in a bear marketJuly 2025 Sector Moves & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Pharvaris Shares Surge After Strong Phase 3 Results for Oral HAE Treatment - MSN
The Technical Signals Behind (PHVS) That Institutions Follow - Stock Traders Daily
Pharvaris Rings the Opening Bell - Nasdaq
Pharvaris Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Pharvaris N.V. (PHVS) Stock Analysis: A Biotechnology Gem With 69% Upside Potential - DirectorsTalk Interviews
What’s the fair value of Pharvaris N.V. stockPortfolio Return Summary & Expert Verified Movement Alerts - mfd.ru
Meme Stocks: Is NextNav Inc Equity Warrant exposed to currency risksPortfolio Growth Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Analysts Set Pharvaris N.V. (NASDAQ:PHVS) Target Price at $40.56 - Defense World
Precision Trading with Pharvaris N.v. (PHVS) Risk Zones - Stock Traders Daily
Pharvaris N.V. (PHVS) Stock Analysis: Navigating A 65% Upside In Biotech Innovations - DirectorsTalk Interviews
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Surprises Report: Can Pharvaris NV stock outperform in a bear marketPrice Action & Expert-Curated Trade Recommendations - baoquankhu1.vn
Layoff Watch: Is Box Inc. a speculative investmentWeekly Market Outlook & Short-Term High Return Ideas - baoquankhu1.vn
Assessing Pharvaris (PHVS) Valuation After Recent Share Price Volatility And DCF Upside Gap - Yahoo Finance
Technical Reactions to PHVS Trends in Macro Strategies - Stock Traders Daily
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts - The Globe and Mail
Pharvaris N.V. (PHVS) Stock Analysis: A Promising 83% Upside Potential Amid Biotech Advancements - DirectorsTalk Interviews
Why Pharvaris N.V. stock attracts high net worth investorsMarket Rally & Reliable Price Breakout Signals - Улправда
Why Pharvaris N.V. stock remains a top recommendationOil Prices & Real-Time Market Sentiment Reports - ulpravda.ru
Will Pharvaris N.V. (9EN) stock split increase liquidity2025 Year in Review & Capital Efficient Trade Techniques - Улправда
Street Watch: Why Pharvaris N.V. stock remains a top recommendationDay Trade & Daily Entry Point Trade Alerts - Улправда
How Pharvaris N.V. (9EN) stock reacts to fiscal policiesJuly 2025 PreEarnings & Low Volatility Stock Suggestions - Улправда
How Pharvaris N.V. stock responds to policy changes2025 Market Outlook & Real-Time Volume Trigger Notifications - Улправда
Pharvaris (NASDAQ:PHVS) Shares Up 9.1%Still a Buy? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Down 5.7%What's Next? - MarketBeat
What analysts say about Pharvaris NV stockInstitutional Buying Trends & Use Smart Algorithms to Pick Better Stocks - earlytimes.in
LongTerm Outlook Is Uravi Defence and Technology Limited a BuyandHold StockEarnings Volatility Patterns & Low Cost Stock Ideas - earlytimes.in
CEO Moves: Is Pharvaris NV stock trading near support levelsMarket Performance Report & High Conviction Buy Zone Alerts - moha.gov.vn
Pharvaris (NASDAQ:PHVS) Raised to “Hold” at Wall Street Zen - Defense World
Trading the Move, Not the Narrative: (PHVS) Edition - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Trading 3.8% Higher – What’s Next? - Defense World
Pharvaris N.V. (PHVS) Stock Analysis: Assessing a 66.61% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Pharvaris Nv Azioni (PHVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):